Epratuzumab
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases[1].
Product Specifications
CAS Number
[205923-57-5]
Product Name Alternative
Antibody hLL 2; AMG-412
UNSPSC
12352203
Target
CD22
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/epratuzumab.html
Purity
99.53
Solubility
10 mM in DMSO
Smiles
[Epratuzumab]
Molecular Weight
(146.58 kDa)
References & Citations
[1]Carnahan J, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003 Sep 1;9 (10 Pt 2) :3982S-90S.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15134349 1 Vial
Lentiviral human CCKBR shRNA (UAS) - Lentiviral human CCKBR shRNA (UAS, GFP) (100)
Ask
View Details 
